The trial will assess samuraciclib plus elacestrant in treating patients with CDK4/6i resistant HR+/HER2- metastatic breast cancer. Credit: Chompoo Suriyo / Shutterstock.

Carrick Therapeutics has dosed the first patient in a Phase II clinical study of samuraciclib (CT7001) in combination with Menarini Group’s elacestrant in patients with CDK4/6i resistant HR+/HER2- metastatic breast cancer.

Samuraciclib is an oral and first-in-class inhibitor of CDK7, while elacestrant is an oral selective estrogen receptor degrader (SERD).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Initially, the study will assess the combination’s pharmacokinetics and tolerability. Later, it will recruit an expansion cohort to assess the longer-term progression-free survival benefits.

ctDNA analysis performed through liquid biopsy will serve as a key component of the study to address two issues, including the benefit level in patients without a detectable ESR1 mutation and the subject selection biomarker potential of TP53-mutation status.

The Phase II study is being carried out in partnership with Menarini as part of a clinical trial collaboration and supply agreement for elacestrant.

See Also:

Carrick Therapeutics CEO Tim Pearson said: “Dosing the first patient in our Phase II clinical trial evaluating the combination of samuraciclib and elacestrant is an important milestone in our goal of improving outcomes for women fighting metastatic breast cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our prior studies have validated the biology for elacestrant with CDK7, and we are eager to evaluate the potential synergistic benefit of this fully oral combination therapy in patients with advanced breast cancer.”

In January, ORSERDU (elacestrant), 345 mg tablets, received approval to treat postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression after a minimum of one line of endocrine therapy.